Learn more about our Market Access and Pricing practice
Ed Schoonveld Practice Lead
Pharmaceutical companies need to better incorporate payer perspectives in drug development and commercial decision making. Increasingly strict payer evidence requirements and intense competition mean companies must develop and articulate stronger payer value propositions.
ZS helps pharmaceutical companies create and execute optimal market access and pricing strategies. At each stage of development, we help you to identify payer and physician benefits and related evidence requirements to support development and commercialization decision making.
ZS’s Market Access & Pricing Services help you:
By Ed Schoonveld
In the cover story of PM360's September 2011 issue, ZS Principal Ed Schoonveld offers guidelines on pricing, positioning, and building consensus to help pharmaceutical companies gain the best possible payer acceptance.
By Ed Schoonveld and Johann Meyer-Christian
Ed Schoonveld and Johann Meyer-Christian report on the structure of Germany's new AMNOG-based pricing system and how its ambiguity may bring a halt to new drug launches.
Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry.